Drugs / anhydrous citric acid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03106922 | Apr 2016 → Jul 2020 | — | Alfasigma S.p.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01065857 | Jan → Jun 2010 | — | Laboratorios Casen-Fleet S.L.U. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07162974 | Jan 2023 → Oct 2024 | urolithiasis | Moscow State University of Medicine and Dentistry | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anhydrous citric acid | “2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).” NCT01065857 ↗2“Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;” NCT03106922 ↗ |